| Axitinib |
ENSG00000117242.7 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000125804.9 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000125804.9 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000132832.5 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000135253.9 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000135253.9 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000136315.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000146666.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000153363.8 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000160336.10 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000163364.5 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000170919.11 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000172250.10 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000172250.10 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000172250.10 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000174171.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000174680.5 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000175701.6 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000175772.10 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000175773.8 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000177112.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000177337.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000177406.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000177757.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000177993.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000178803.6 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000178803.6 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000178947.8 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000178977.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000178977.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000179219.5 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000179406.6 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000179743.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000179935.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000180279.5 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000180846.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000181798.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000182057.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000182109.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000182109.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000182310.8 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000182376.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000182648.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000183242.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000184068.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000184274.3 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000185168.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000185203.7 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000188185.7 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000188206.5 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000188660.3 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000189149.7 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000189223.9 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000189223.9 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000189238.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000197099.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000197813.4 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000198106.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000198221.7 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000198468.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000203307.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000203325.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000203362.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000203364.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000203496.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000203588.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000203650.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000203865.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000203999.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000203999.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000204706.10 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000204706.10 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000204791.4 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000204802.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000204832.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000204837.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000204860.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000204949.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000205037.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000205444.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000205885.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000206113.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000206140.5 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000206142.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000206573.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000211683.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000212552.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000212978.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000213793.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000213904.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000213963.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000214146.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000214184.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000214432.5 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000214559.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000214851.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000214894.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000214955.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000215039.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000215068.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000215068.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000215241.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000215394.4 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000215417.6 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000215424.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000215841.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000215869.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000217576.7 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000218018.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000219665.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000220161.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000221817.5 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000222043.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000223356.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000223396.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000223401.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000223473.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000223478.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000223522.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000223546.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000223573.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000223576.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000223579.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000223598.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000223598.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000223635.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000223653.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000223653.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000223695.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000223695.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000223695.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000223697.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000223701.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000223711.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000223711.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000223714.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000223749.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000223749.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000223759.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000223813.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000223839.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000223855.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000223855.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000223901.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000223901.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000223979.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224020.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000224023.6 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224046.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224050.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000224078.8 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000224079.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000224079.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224086.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000224116.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000224157.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000224165.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224209.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000224222.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000224281.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224292.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224468.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000224468.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000224565.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000224592.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000224609.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000224621.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000224635.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000224635.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000224660.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000224660.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224660.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000224666.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000224687.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000224699.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224699.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000224707.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000224715.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000224715.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000224764.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000224799.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000224822.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000224844.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000224848.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000224897.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000224905.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224939.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000224945.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000224969.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000224972.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000224985.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000225030.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000225030.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000225032.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000225039.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000225075.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000225075.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000225077.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000225146.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000225163.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000225177.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000225180.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000225194.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000225205.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000225205.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000225206.4 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000225210.5 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000225213.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000225216.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000225235.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000225265.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000225331.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000225331.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000225334.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000225335.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000225335.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000225335.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000225361.3 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000225393.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000225434.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000225434.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000225439.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000225439.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000225446.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000225521.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000225535.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000225611.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000225684.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000225760.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000225767.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000225778.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000225791.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000225836.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000225836.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000225839.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000225891.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000225914.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000225945.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000225953.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000225969.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000225969.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000225969.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000225973.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000225975.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000226029.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000226047.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000226053.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000226067.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000226091.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000226172.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000226263.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000226266.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000226291.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000226310.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000226330.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000226330.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000226352.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000226381.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000226386.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000226416.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000226445.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000226445.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000226465.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000226472.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000226562.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000226609.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000226645.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000226669.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000226690.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000226746.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000226746.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000226756.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000226797.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000226816.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000226819.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000226851.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000226853.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000226856.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000226876.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000226890.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000226900.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000226904.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000226920.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227036.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227053.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227060.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000227068.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227070.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227071.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227083.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227110.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000227117.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227155.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227188.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000227193.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000227214.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227214.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000227237.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227256.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000227285.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227354.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227354.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000227373.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000227375.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000227388.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227403.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227409.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227456.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000227477.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000227486.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227486.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000227492.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000227492.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000227496.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000227502.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000227512.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227527.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227606.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000227674.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000227681.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000227698.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000227704.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000227712.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000227740.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000227740.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000227741.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000227741.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227773.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000227773.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000227811.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000227857.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227857.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000227888.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000227896.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000227938.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000227953.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000227959.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000227963.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000227963.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000228005.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000228010.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000228013.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228043.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000228079.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000228084.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228106.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000228113.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228127.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228140.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228141.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000228141.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000228150.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000228150.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228237.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000228237.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000228242.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000228251.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000228302.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000228315.7 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228372.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000228386.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000228389.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000228393.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228393.3 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000228395.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228397.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228414.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228436.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228486.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228486.5 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000228526.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000228527.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000228598.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228624.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228639.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000228661.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228677.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228677.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000228679.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000228686.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000228701.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000228719.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228748.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000228763.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000228789.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000228794.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000228817.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000228839.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000228857.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228878.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000228889.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000228918.3 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000228962.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000228962.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000228989.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000229043.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000229118.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000229154.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000229180.4 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000229190.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000229203.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000229228.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000229267.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000229291.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000229291.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000229311.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000229356.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000229368.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000229388.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000229393.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000229431.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000229525.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000229556.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000229563.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000229591.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000229628.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000229656.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000229666.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000229688.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000229702.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000229739.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000229750.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000229852.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000229867.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000229869.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000229874.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000229893.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000229896.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000229905.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000229956.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000229970.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000229980.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000229996.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000230054.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000230058.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000230074.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000230082.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000230091.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230102.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230102.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000230113.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000230148.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000230176.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000230289.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000230303.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230303.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000230310.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000230314.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000230319.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000230337.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000230337.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230424.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230479.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000230487.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230506.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000230513.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000230534.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000230565.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000230565.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230613.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230613.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000230633.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000230658.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000230699.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000230736.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230736.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000230736.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000230753.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000230812.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000230825.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000230899.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000230925.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230939.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000230943.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231010.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000231024.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231025.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000231028.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231050.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231050.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000231154.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000231154.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231170.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231226.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231290.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231298.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231305.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231305.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000231312.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231327.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231335.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231393.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231407.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231439.3 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000231441.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000231486.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231507.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231509.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000231528.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000231563.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231566.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000231595.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000231607.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000231611.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000231628.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000231628.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000231636.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000231636.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000231638.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000231711.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000231721.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231728.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000231789.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000231794.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000231829.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000231840.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000231865.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000231889.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000231903.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231903.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000231908.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000231920.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000231944.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000231966.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000232043.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000232063.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232077.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000232104.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232116.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000232117.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000232224.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000232224.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232233.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000232295.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000232298.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232386.5 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000232386.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232442.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000232453.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232470.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000232487.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000232487.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000232504.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232533.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232564.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232586.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232593.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232611.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232642.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000232645.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232648.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000232650.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000232656.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000232693.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232693.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000232696.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000232710.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232729.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000232759.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232827.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232828.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232874.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000232896.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232912.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000232931.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000232936.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232936.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000232949.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000232969.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000232995.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233016.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000233061.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000233077.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233108.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233108.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000233137.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000233144.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000233178.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233207.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000233221.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000233230.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233237.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000233237.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000233237.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000233237.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233244.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233246.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000233296.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000233351.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233358.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233411.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233411.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000233421.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233429.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233483.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000233517.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000233547.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000233621.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233627.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233643.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000233654.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233665.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000233695.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000233783.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000233799.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233817.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000233818.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233834.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000233845.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233848.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000233860.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000233862.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000233864.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000233912.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000233912.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234006.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000234019.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234026.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000234028.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234062.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000234070.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234076.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234141.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234147.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234149.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000234149.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234160.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234171.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000234181.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000234181.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000234183.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234197.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234199.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000234206.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000234206.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000234215.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000234230.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000234255.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234261.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000234281.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234290.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000234290.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234350.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000234393.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000234393.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234396.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234449.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000234478.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000234494.3 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000234509.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234546.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000234571.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000234572.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234584.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234614.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234617.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000234663.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234663.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234665.4 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000234676.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000234690.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234694.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234698.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000234740.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000234741.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000234753.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000234771.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234807.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000234807.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000234818.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000234832.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234869.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000234869.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000234884.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234884.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000234913.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000234915.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234917.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000234936.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000234945.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000234978.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000234996.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000235033.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235042.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235066.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000235078.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000235106.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000235111.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000235204.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000235204.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000235214.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235262.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000235262.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000235326.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000235358.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000235381.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000235419.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235501.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235501.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000235527.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000235590.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000235590.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000235635.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000235635.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235663.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235703.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000235724.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235725.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235726.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000235770.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000235781.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235802.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000235831.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000235837.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000235848.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235852.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000235852.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000235872.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000235884.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000235897.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000235903.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000235908.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000235908.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000235910.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000235954.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000235999.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236051.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000236095.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000236095.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000236098.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000236115.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000236137.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000236140.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000236144.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000236153.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236199.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000236200.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000236204.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236212.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236269.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000236305.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236308.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000236333.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000236345.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000236345.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236404.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000236426.3 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000236432.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000236438.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000236472.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000236510.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000236519.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000236520.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000236528.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000236528.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236581.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000236581.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000236617.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000236671.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236753.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236760.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000236846.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236861.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000236894.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000236901.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236901.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000236914.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236915.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000236935.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000236936.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236953.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000236983.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000236991.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000237015.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237017.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000237036.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237036.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000237037.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237133.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237133.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000237166.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000237187.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000237301.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000237310.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237310.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000237328.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237328.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000237331.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237346.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237436.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237453.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000237461.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237461.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000237461.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000237476.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000237481.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000237505.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000237525.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000237588.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000237594.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000237595.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000237604.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000237609.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237609.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000237689.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000237697.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000237697.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000237721.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000237721.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000237756.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000237756.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237764.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000237805.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000237807.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000237813.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000237836.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000237836.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000237877.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000237892.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000237903.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000237927.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000237928.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000237938.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000237943.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000237945.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000237978.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000238018.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000238018.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000238039.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000238045.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000238107.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000238121.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000238123.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000238140.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000238198.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000238210.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000238273.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000238273.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000238279.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000238279.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000238280.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000238287.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000239213.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000239335.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000239462.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000239480.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000239498.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000239523.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000239569.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000239593.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000239636.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000239653.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000239653.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000239705.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000239774.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000239774.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000239801.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000239920.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000240005.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000240057.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000240093.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000240137.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000240143.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000240143.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000240211.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000240254.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000240350.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000240373.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000240373.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000240476.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000240549.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000240571.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000240618.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000240758.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000240770.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000240859.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000240875.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000240996.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000241014.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000241155.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000241180.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000241219.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000241280.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000241288.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000241288.3 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000241316.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000241525.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000241570.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000241572.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000241684.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000241769.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000241770.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000241818.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000241933.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000242012.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000242154.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000242190.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000242349.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000242516.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000242553.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000242611.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000242622.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000242686.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000242687.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000242753.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000242798.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000242861.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000243055.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000243069.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000243176.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000243176.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000243176.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000243479.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000243701.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000244055.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000244063.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000244198.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000244252.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000244265.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000244268.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000244327.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000244332.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000244342.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000244393.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000244459.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000244625.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000244676.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000244757.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000244791.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000244952.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000244968.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000244968.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000245059.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000245146.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000245213.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000245275.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000245281.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000245281.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000245311.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000245479.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000245534.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000245534.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000245556.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000245571.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000245598.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000245614.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000245748.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000245750.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000245750.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000245857.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000245910.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000246067.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000246225.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000246225.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000246263.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000246308.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000246323.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000246334.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000246523.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000246526.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000246548.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000246582.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000246740.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000246777.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000246790.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000246859.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000246859.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000247081.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000247092.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000247134.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000247151.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000247199.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000247199.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000247213.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000247228.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000247271.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000247311.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000247363.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000247516.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000247679.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000247708.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000247708.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000247735.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000247774.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000247809.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000247828.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000247982.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000247982.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000248019.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000248161.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000248175.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000248222.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000248238.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000248240.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000248243.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000248356.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000248367.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000248461.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000248468.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000248468.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000248515.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000248537.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000248554.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000248559.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000248559.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000248559.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000248647.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000248664.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000248664.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000248693.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000248714.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000248774.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000248774.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000248810.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000248973.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000249001.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000249042.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000249241.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000249279.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000249356.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000249359.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000249406.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000249456.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000249492.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000249502.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000249532.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000249532.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000249574.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000249631.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000249635.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000249650.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000249655.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000249664.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000249685.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000249685.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000249685.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000249786.3 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000249791.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000249791.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000249825.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000249835.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000249870.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000249894.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000249898.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000249942.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000250061.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000250073.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000250081.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000250106.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000250107.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000250156.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000250220.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000250280.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000250295.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000250295.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000250295.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000250303.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000250320.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000250410.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000250432.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000250508.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000250548.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000250548.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000250590.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000250596.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000250692.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000250714.3 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000250874.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000250874.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000250900.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000250909.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000250910.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000250938.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000250988.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000251026.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000251085.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000251131.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000251131.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000251141.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000251143.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000251169.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000251175.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000251175.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000251175.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000251194.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000251194.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000251221.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000251365.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000251379.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000251417.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000251442.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000251455.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000251538.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000251556.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000251577.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000251580.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000251604.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000251611.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000251615.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000251666.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000253106.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000253111.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253121.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253133.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253167.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000253167.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000253174.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000253197.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253263.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000253266.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253284.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000253307.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000253307.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000253327.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000253335.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253347.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253372.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000253372.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000253392.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000253392.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000253395.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253399.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000253404.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000253408.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000253476.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000253477.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000253508.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000253532.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253591.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253595.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000253616.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253669.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000253671.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253696.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253730.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000253730.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000253754.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000253764.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253773.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000253802.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000253829.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000253837.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000253837.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000253837.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000253848.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000253878.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000253921.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000254027.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000254027.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000254044.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254081.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254094.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000254109.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000254129.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000254154.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254162.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000254177.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000254180.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000254204.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000254207.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000254207.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000254231.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000254263.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000254281.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000254286.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000254286.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254295.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000254295.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000254427.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000254431.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254432.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000254450.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000254458.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254473.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000254556.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254560.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000254574.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254592.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254604.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000254664.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000254694.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000254694.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000254731.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000254731.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254756.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000254837.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254846.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000254855.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000254855.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254855.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000254872.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000254900.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000254929.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000254936.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000254985.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000255020.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000255020.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000255045.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000255135.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255135.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000255142.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255160.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255164.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000255165.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255176.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000255202.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000255308.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255310.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000255320.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000255326.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000255343.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000255348.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000255355.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255409.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000255421.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000255435.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000255443.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000255443.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255449.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000255471.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000255487.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000255495.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000255503.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255507.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000255539.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000255559.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000255568.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255571.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000255650.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000255651.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255669.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255689.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000255723.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000255843.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000255893.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000255966.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000255989.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000256001.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000256092.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000256116.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000256128.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000256151.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000256249.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000256312.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000256442.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000256443.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000256448.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000256458.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000256538.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000256576.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000256603.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000256690.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000256742.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000256862.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000256967.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000257004.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000257058.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000257135.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000257151.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000257156.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000257167.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000257202.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000257221.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000257261.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000257264.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000257279.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000257322.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000257354.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000257366.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000257381.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000257381.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000257391.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000257449.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000257496.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000257526.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000257556.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000257556.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000257557.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000257568.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000257647.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000257698.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000257718.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000257735.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000257815.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000257831.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000257894.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000257910.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000257931.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000257953.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000257999.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000258001.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000258086.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000258122.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000258274.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000258301.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000258314.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000258355.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000258378.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000258413.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000258441.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000258450.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000258451.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000258458.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000258534.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000258561.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000258569.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000258667.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000258682.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000258701.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000258704.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000258704.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000258725.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000258730.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000258733.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000258735.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000258754.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000258766.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000258789.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000258825.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000258857.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000258914.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000258920.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000258959.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000258983.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000259006.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259026.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259039.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000259062.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000259065.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259088.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259138.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000259138.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000259172.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000259234.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259234.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259238.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000259250.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000259274.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259275.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259287.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259287.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000259306.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000259319.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000259319.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000259322.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000259327.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259343.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000259349.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259349.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000259364.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000259396.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259398.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259407.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000259408.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259408.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000259417.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000259437.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259438.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000259438.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259453.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000259476.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000259515.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259520.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000259521.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000259542.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259548.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000259583.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000259583.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000259584.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259589.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000259590.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000259595.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000259595.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259623.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000259631.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259652.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000259654.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259656.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259659.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000259659.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000259687.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259687.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000259694.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000259709.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259732.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259744.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259758.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000259768.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000259768.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000259774.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000259774.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000259775.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259783.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259792.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000259802.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000259806.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000259820.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000259826.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259863.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000259877.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259883.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259888.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259899.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259915.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000259921.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000259926.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000259942.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000259959.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000259994.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000259994.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000260005.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260005.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260008.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260018.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260021.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260025.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000260037.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260052.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260059.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260059.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000260060.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000260065.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000260086.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000260101.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000260156.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260167.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260177.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260179.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260194.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000260196.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260213.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000260219.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260236.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260239.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260248.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000260277.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260278.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000260278.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260278.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000260288.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260336.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260349.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000260352.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260367.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260368.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000260388.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260392.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000260394.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260400.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000260417.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000260425.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000260430.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260439.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000260441.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000260447.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000260448.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260475.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260475.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000260493.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260493.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000260495.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260495.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260498.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260517.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260536.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260550.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260565.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000260572.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000260577.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260586.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000260588.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000260589.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260619.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260626.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260630.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000260635.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000260641.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260645.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000260646.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000260646.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000260648.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000260664.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260743.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000260744.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260757.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260773.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260792.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260792.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000260793.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260796.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260805.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260831.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000260831.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260837.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000260874.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000260884.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260891.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000260895.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000260905.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000260910.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000260911.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000260912.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260912.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000260917.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000260924.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000260936.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260938.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000260938.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260948.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000260948.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000260954.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000260971.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000260973.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000260978.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000260986.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000260988.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261000.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000261002.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000261015.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000261024.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000261040.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000261043.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261049.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261064.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000261070.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000261083.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000261092.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000261094.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261096.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261117.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000261118.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261135.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000261141.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261172.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000261183.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000261200.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000261252.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000261254.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000261267.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000261295.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000261305.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000261314.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000261326.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000261337.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000261338.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000261338.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261342.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000261353.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000261360.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261373.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261373.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000261379.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261386.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261396.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261407.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261420.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000261423.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261431.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261433.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000261434.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000261438.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000261469.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000261474.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000261490.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000261505.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000261523.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261560.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000261589.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000261610.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000261613.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000261616.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000261644.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000261662.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000261673.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261695.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261737.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261760.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261765.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000261766.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261770.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000261798.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000261824.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000261839.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261840.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261840.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000261864.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000261879.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000261924.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000261924.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000262001.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000262115.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000262136.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000262147.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000262171.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000262185.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000262202.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000262202.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000262312.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000262313.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000262434.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000262585.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000262619.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000262652.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000262721.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000262772.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000262873.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000262873.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000262873.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000262905.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000263004.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000263050.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000263063.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000263072.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000263164.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000263176.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000263321.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000263325.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000263327.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000263338.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000263350.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000263370.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000263388.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000263412.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000263470.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000263499.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000263531.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000263612.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000263624.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000263627.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000263674.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000263680.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000263680.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000263727.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000263884.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000263884.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000263916.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000263916.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000263924.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000264012.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000264125.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000264167.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000264167.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000264167.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000264269.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000264469.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000264647.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000264647.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000264673.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000264673.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000264812.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000264859.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000264860.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000264937.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000264937.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000265010.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000265094.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000265185.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000265205.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000265246.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000265342.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000265496.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000265511.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000265625.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000265702.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000265743.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000265791.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000265888.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000265933.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000265943.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000266010.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000266040.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000266111.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000266120.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000266236.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000266283.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000266289.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000266371.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000266401.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000266411.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000266441.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000266473.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000266473.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000266521.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000266538.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000266541.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000266651.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000266677.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000266709.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000266717.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000266717.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000266801.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000266824.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000266850.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000266896.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000266897.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000266916.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000266921.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000266926.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000266930.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000266935.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000266947.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000266957.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000266968.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000266970.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000266975.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000266993.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000267010.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000267010.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267018.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267040.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000267053.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000267064.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267082.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000267108.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000267117.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000267118.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000267143.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000267152.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000267183.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267191.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000267199.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000267199.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000267212.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267231.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267249.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000267255.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000267272.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000267274.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000267280.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000267288.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000267289.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000267289.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000267296.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000267304.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000267308.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000267344.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267345.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267348.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267390.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000267390.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267397.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000267419.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000267419.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000267454.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000267476.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000267481.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000267491.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000267563.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000267565.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267567.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000267651.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267662.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000267667.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000267705.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000267705.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267737.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000267751.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000267751.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000267758.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000267758.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000267776.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000267778.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000267786.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000267787.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000267787.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000267798.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000267834.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267871.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000267898.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267919.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000267919.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000267919.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000267939.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000267940.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000268006.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000268006.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000268015.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000268061.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000268081.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000268095.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000268186.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000268199.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000268230.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000268262.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000268340.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000268375.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000268388.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000268401.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000268458.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000268499.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000268516.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000268649.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000268686.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000268836.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000268895.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000268912.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000268947.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000268970.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000268970.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000269019.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000269044.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000269082.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269148.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000269177.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269220.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000269290.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000269290.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000269290.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000269293.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000269397.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000269399.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000269481.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269486.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000269487.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000269524.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000269534.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000269560.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000269609.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000269609.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000269640.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269694.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269707.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000269720.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269825.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000269834.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000269889.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269895.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269901.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000269901.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269910.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000269918.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000269923.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000269940.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000269942.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000269947.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000269949.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000269951.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000269954.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000269956.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000269958.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000269959.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000269961.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000269962.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000269966.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000270000.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000270006.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000270006.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270009.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000270012.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270019.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270020.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000270022.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000270022.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000270028.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000270031.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000270031.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000270049.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270061.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270062.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000270062.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000270062.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270062.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000270067.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000270068.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270068.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000270069.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270081.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000270083.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000270095.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270102.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000270102.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000270104.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000270105.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000270110.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000270116.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000270124.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000270130.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270140.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000270141.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000270143.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000270171.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000270173.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000270184.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000270189.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000270246.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000270265.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000270346.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000270361.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000270522.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000270571.2 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000270580.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000270605.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000270640.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000270659.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000270704.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000270761.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000270820.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000270949.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000270988.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000270996.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000271086.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000271133.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000271147.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000271151.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000271172.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000271228.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000271265.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000271308.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000271344.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000271347.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000271359.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000271367.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000271384.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000271387.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000271398.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000271533.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000271554.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000271554.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000271554.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000271646.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000271727.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000271732.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000271734.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000271737.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000271737.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000271743.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000271778.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000271780.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000271803.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000271803.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000271820.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000271824.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000271826.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000271830.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000271835.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000271843.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000271843.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000271849.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000271851.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000271856.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000271874.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000271894.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000271914.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000271927.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000271964.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000271967.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000271978.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000271983.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000271991.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000271992.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272002.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000272003.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272009.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272010.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272023.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000272029.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272029.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000272040.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272043.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272048.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272053.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272068.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000272077.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272081.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272092.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272102.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000272103.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272112.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000272121.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272141.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000272144.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000272148.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272156.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000272161.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272168.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000272180.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000272180.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272192.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272192.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272211.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272217.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272217.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272219.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272250.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272254.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272264.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000272275.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272288.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272301.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000272308.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272312.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272327.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000272328.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272341.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272361.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272368.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272368.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272368.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000272369.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272369.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272370.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272374.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272375.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272377.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272379.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000272382.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272384.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272384.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000272389.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272403.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000272411.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272425.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000272438.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272444.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272449.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000272452.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000272452.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272465.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272512.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272520.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272520.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272524.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272524.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272537.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272562.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272567.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272576.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272583.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272583.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000272610.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000272620.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000272622.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272644.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272650.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272657.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000272657.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272659.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Axitinib |
ENSG00000272662.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272669.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272682.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272682.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272682.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272689.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272689.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272689.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272690.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272695.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000272696.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272696.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272702.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272719.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272721.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272721.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272733.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272734.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000272735.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272735.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272764.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272764.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000272769.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272792.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000272800.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272808.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000272828.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272828.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000272829.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272834.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000272846.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272853.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272861.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000272870.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000272870.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000272888.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000272894.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272905.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000272913.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272917.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000272977.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000273000.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273001.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273002.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273002.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273004.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273007.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000273014.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000273026.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273026.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000273027.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273032.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000273038.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000273061.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273061.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Axitinib |
ENSG00000273125.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000273125.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000273125.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000273125.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273131.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000273132.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000273162.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000273164.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273174.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000273175.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273181.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000273183.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000273186.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000273188.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000273190.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000273190.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273203.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000273233.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000273243.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273272.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000273290.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273302.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000273302.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000273305.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000273307.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000273308.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273319.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000273342.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273342.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273343.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000273350.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000273352.1 |
Predicted lncRNA |
Sarcoma |
|
| Axitinib |
ENSG00000273353.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000273353.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000273355.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000273355.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273365.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000273373.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000273375.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000273384.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000273402.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Axitinib |
ENSG00000273406.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Axitinib |
ENSG00000273416.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000273416.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273424.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273428.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000273428.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000273428.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Axitinib |
ENSG00000273442.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Axitinib |
ENSG00000273447.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Axitinib |
ENSG00000273448.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Axitinib |
ENSG00000273464.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Axitinib |
ENSG00000273474.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Axitinib |
ENSG00000273476.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Axitinib |
ENSG00000273483.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Axitinib |
ENSG00000273486.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
